Mon, 26th Oct 2020 14:17
Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Screens first patient in exploratory field study of Grass MATA MPL immunotherapy on patient who suffer from allergic symptoms when exposed to grass.
Current stock price: 13.29 pence
Year-to-date change: up 30%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
(Alliance News) - Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect ...
(Alliance News) - Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further funding soon.
Allergy Thera. (AGY)